Identification of premature ovarian failure patients with underlying autoimmunity. 2000

G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
Immunobiology Laboratory, Massachusetts General Hospital-East, Charlestown, USA.

Although known causes of premature ovarian failure (POF) include X chromosome deletions, radiation and chemotherapy, and genetic defects of the gonadotropin hormones or receptors, at least one third to one half of cases remain idiopathic. A significant proportion of patients with apparently idiopathic POF have some evidence for an autoimmune etiology. However, the only gold standard for detecting autoimmune causes of immune ovarian destruction has been invasive ovarian biopsy. Serum antibodies to ovarian and other self-tissue have been described in up to one third of women with POF, but the tests are not well standardized, not well correlated with ovarian histology, and highly variable. Recently, specific defects of expression of cell surface markers on peripheral blood lymphocytes have been shown to identify, in population-based studies, individuals destined to develop autoimmune pancreatic destruction and type I diabetes mellitus, even before any other evidence of autoimmunity. We, therefore, sought to test the ability of cell surface marker expression in women with POF to identify autoimmune defects. Seventeen women with POF, 11 of whom had positive antibody titers to ovary, thyroid, or antinuclear antibody, were studied on at least two occasions and compared in blinded fashion with normal controls and patients with autoimmune type I diabetes mellitus. The most useful marker for identifying autoimmunity was the surface density of conformationally correct HLA class I molecules on macrophages, a structure essential for T cell education. Using this marker, 7 of the 9 patients with autoantibodies and 3 of the 8 patients without autoantibodies were identified as having evidence of a defect in self-antigen presentation similar to that of type I diabetics (chi-square, p = 0.03). Subsequent testing identified antismooth muscle antibodies in 1 of the women with a defect of HLA class I molecules but no previously identified autoimmunity. In addition, there were increased numbers of CD8 T cells in both autoimmune POF and insulin-dependent diabetes mellitus (IDDM) patients. Exclusive to POF patients was a statistically significant increase in CD8 density on T cells. This was most prominent in POF patients with an underlying autoimmune etiology. These data further support a role for autoimmunity in POF patients and suggest that the further development of cell surface markers in combination with other diagnostic tests could result in diagnosis before the development of complete ovarian failure. The possibility for disease-specific therapy to prevent further autoimmune ovarian damage in selected POF patients is also envisioned.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D015395 Histocompatibility Antigens Class I Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells. Class I Antigen,Class I Antigens,Class I Histocompatibility Antigen,Class I MHC Protein,Class I Major Histocompatibility Antigen,MHC Class I Molecule,MHC-I Peptide,Class I Histocompatibility Antigens,Class I Human Antigens,Class I MHC Proteins,Class I Major Histocompatibility Antigens,Class I Major Histocompatibility Molecules,Human Class I Antigens,MHC Class I Molecules,MHC-I Molecules,MHC-I Peptides,Antigen, Class I,Antigens, Class I,I Antigen, Class,MHC I Molecules,MHC I Peptide,MHC I Peptides,Molecules, MHC-I,Peptide, MHC-I,Peptides, MHC-I
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016649 Primary Ovarian Insufficiency Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene. Gonadotropin-Resistant Ovary Syndrome,Ovarian Failure, Premature,Resistant Ovary Syndrome,FMR1-Related Primary Ovarian Insufficiency,Fragile X Premature Ovarian Failure,Fragile X-Associated Primary Ovarian Insufficiency,Hypergonadotropic Ovarian Failure, X-Linked,Premature Ovarian Failure,Premature Ovarian Failure 1,Premature Ovarian Failure, X-Linked,Primary Ovarian Insufficiency, Fragile X-Associated,X-Linked Hypergonadotropic Ovarian Failure,FMR1 Related Primary Ovarian Insufficiency,Fragile X Associated Primary Ovarian Insufficiency,Gonadotropin Resistant Ovary Syndrome,Hypergonadotropic Ovarian Failure, X Linked,Ovarian Insufficiency, Primary,Premature Ovarian Failure, X Linked,Primary Ovarian Insufficiency, Fragile X Associated,X Linked Hypergonadotropic Ovarian Failure

Related Publications

G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
December 1993, Journal of endocrinological investigation,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
February 1997, Endocrine reviews,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
August 2007, Current opinion in obstetrics & gynecology,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
January 1991, International journal of fertility,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
January 1989, European journal of obstetrics, gynecology, and reproductive biology,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
July 1993, Clinical endocrinology,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
February 1998, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
August 2015, Iranian journal of reproductive medicine,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
December 2010, Fertility and sterility,
G Yan, and D Schoenfeld, and C Penney, and K Hurxthal, and A E Taylor, and D Faustman
July 2011, Nature reviews. Endocrinology,
Copied contents to your clipboard!